博来霉素-丝裂霉素C治疗晚期女性生殖道鳞状细胞癌
Bleomycin-mitomycin C in advanced squamous cell carcinoma of the female genital tract.
作者信息
Copas P, Dyer M, Smithson L G, Hall D J
出版信息
Obstet Gynecol. 1983 Mar;61(3):308-10.
Bleomycin and mitomycin C have been reported to be active against advanced squamous cell carcinoma of the uterine cervix. Miyamoto et al reported a total response rate of 93% and complete response in 80% of the first 15 patients treated by sequential combination of bleomycin and mitomycin C. Updated results by Miyamoto reveal an 88.3% total response rate with a 65.3% complete response. However, others have reported poor results using the protocol outlined by Miyamoto. Using this protocol, 11 patients with advanced squamous cell carcinoma were treated at the authors' institution. There were no complete responses: one patient with partial response (9%), four with stable disease (36%), and six (55%) with progressive disease.
据报道，博来霉素和丝裂霉素C对晚期子宫颈鳞状细胞癌有效。宫本等人报告称，在前15例接受博来霉素和丝裂霉素C序贯联合治疗的患者中，总缓解率为93%，完全缓解率为80%。宫本更新后的结果显示，总缓解率为88.3%，完全缓解率为65.3%。然而，其他人使用宫本概述的方案报告的结果不佳。使用该方案，作者所在机构对11例晚期鳞状细胞癌患者进行了治疗。没有完全缓解的病例：1例部分缓解（9%），4例病情稳定（36%），6例（55%）病情进展。
Zotero 插件